Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
about
Lipid-lowering efficacy of rosuvastatinEffect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteersRole of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia.Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin.Characterization of ADME gene variation in 21 populations by exome sequencing.Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.Seventeen years of statin pharmacogenetics: a systematic review.Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).Renal Drug Transporters and Drug Interactions.Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?Response to perioperative statin therapy in cardiac surgery: a matter of race and timing?Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.PharmGKB summary: very important pharmacogene information for ABCG2.Statin drug interactions and related adverse reactions: an update.Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.Statin Responses in Chinese Patients.
P2860
Q24187891-E68FC0EA-BBF4-427B-8E39-968486D82918Q33686542-68CFD88E-0F1A-4A2F-8EF1-2A9DED27F00EQ34871636-7D23E159-D9FF-43F7-BA20-89D05359F3A7Q36808178-813CDE23-1223-4894-B119-ABC5A1CF4A77Q36956524-FE882600-148F-435D-A69A-9FE59AC7B6EBQ37388209-EAFAF6CC-21B0-4E92-9704-6747C18AA1FAQ37619264-7947FD2E-E840-44A9-8EC5-0B092C28822EQ37640762-499673F0-147E-49DC-8299-39B1ED88E6A7Q38155218-0D7BE5CB-2431-4586-B306-5DC8CA6BFE0DQ38207943-EFFB22D1-DCA8-4242-A0C8-E7131F543C62Q38208727-4941CCAF-3C99-4BC6-8464-C510D3972A8BQ38663481-8DAEE4E4-3B87-452F-84EA-4F5B6987E8FDQ38670109-469ABEB7-B03C-48D1-B444-200DF73D8350Q39034284-70DB5D24-BA3B-49E8-A2F7-296D196E6A9AQ39140289-2D819A8E-36FA-406B-B901-C11359BDDD72Q40129655-5CBA7103-D0FB-45FB-9FF4-49C4CCA19B89Q41512597-0717EA5B-5876-4F70-9422-6C982886D92CQ42012894-F3204C7C-9C8A-4875-AC8D-BE3B732CC377Q42384682-DD911FD8-ADEC-488C-AA74-A9DA16E3ED96Q44737065-AEBACA59-1043-42FF-AD05-0784E3B9E64BQ45243894-68B5C31C-236A-48A4-B1F5-565265F9572CQ46018199-26D56EA1-E7AB-4EA5-AE8A-31078F676431Q48145497-8100B209-87E6-4CD4-8E77-380F341AEB0AQ50108375-192E09E7-BABD-4DAD-9207-157EFC485968Q51304354-B7D7095A-2B9E-4F16-BDB3-7C8AA0CF1916Q51481319-D43A6EFC-9206-4D49-9857-4C5BA62C1ADCQ53099880-53860F29-BBF8-43F3-84F8-77DAB3511F07Q53611791-1C453041-9EF9-43F6-9C6F-1BF6E72741CAQ53736039-0602B5F9-1BD1-485E-B3A8-DB48BA1737C4Q55034030-F0E05B16-8403-4AA5-8375-6EB55618ED0C
P2860
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Effects of polymorphisms in AB ...... response in Chinese patients.
@en
Effects of polymorphisms in AB ...... response in Chinese patients.
@nl
type
label
Effects of polymorphisms in AB ...... response in Chinese patients.
@en
Effects of polymorphisms in AB ...... response in Chinese patients.
@nl
prefLabel
Effects of polymorphisms in AB ...... response in Chinese patients.
@en
Effects of polymorphisms in AB ...... response in Chinese patients.
@nl
P2093
P2860
P356
P1433
P1476
Effects of polymorphisms in AB ...... response in Chinese patients.
@en
P2093
Brian Tomlinson
Chun-Kwok Wong
Chung-Shun Ho
Hon-Kit Lee
Sandra Sh Lui
P2860
P304
P356
10.2217/PGS.13.115
P577
2013-08-01T00:00:00Z